risks of glp-1 drugs Part 2 a 3-Part Series; Medications for Weight Loss glp-1 drugs long term effects

Can cause electrolyte imbalances with daily use

That study enrolled 3,417 adults with obesity or overweight and without type 2 diabetes, and showed a mean weight loss of 22.7% at 68 weeks in patients who remained on treatment

In July of 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for $5.3 billion, and one year later AstraZeneca purchased the Bristol-Myers Squibb share of the diabetes joint venture

As frustrating as all the hoop-jumping sounds, it's better than losing coverage outright

Theyre also cheaper, easier to access, and typically have fewer side effects

PubMed Central , doi:10.4239/wjd.v13.i3.129